SCHEDULE: Janus Henderson Exits Larimar Therapeutics Stake

Janus Henderson Group plc has reported a 0.0% beneficial ownership in Larimar Therapeutics, Inc., indicating a full divestment of its previous holdings.

Summary

• Janus Henderson Group plc has reported a change in its beneficial ownership in Larimar Therapeutics, Inc. via an Amendment No. 5 to Schedule 13G.
• Janus Henderson Group plc, along with its subsidiaries, now beneficially owns 0 shares of Larimar Therapeutics' Common Stock.
• This represents 0.0% of the class of securities.
• The event date requiring this statement is March 31, 2025.
• Janus Henderson Group plc is classified as a parent holding company, with its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML acting as registered investment advisers.
• A certification states that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Larimar Therapeutics.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment of shares in Larimar Therapeutics by Janus Henderson Group plc, which is generally a negative signal from an institutional investor.

Positives

• Janus Henderson's previous holdings were for ordinary course of business, not for control purposes.

Negatives

• Janus Henderson Group plc has fully divested its stake in Larimar Therapeutics, indicating a lack of current investment interest from this institutional investor.

Risks

• The divestment by an institutional investor like Janus Henderson could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy regarding Larimar Therapeutics.

Future Outlook

No forward-looking statements or guidance regarding Larimar Therapeutics' future performance or strategic direction are provided. This report solely concerns a change in beneficial ownership by an institutional investor.

Management Comments

• A certification states that the securities were acquired and held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

A change in an institutional investor's position in Larimar Therapeutics, a biotechnology company, has occurred. Such divestments by major asset managers like Janus Henderson can sometimes influence market perception within the biotech sector, especially if the company is in clinical development stages and relies on investor confidence.

Comparison to Industry Standards

• This is a standard Schedule 13G filing reporting a change in beneficial ownership below the reporting threshold. There are no specific financial results or operational metrics to compare against industry benchmarks or comparable companies. The divestment itself is a transactional event by an investor, not a performance metric of Larimar Therapeutics.

Stakeholder Impact

• Shareholders: Existing shareholders might view the divestment by Janus Henderson negatively, potentially leading to downward pressure on the stock price.
• Potential Investors: New investors might be deterred by the exit of a large institutional holder.

Next Steps

• No specific future actions or milestones for Larimar Therapeutics are outlined. This is a compliance filing by an investor.

Key Dates

Recommendation

The complete divestment of shares by Janus Henderson Group plc, a major institutional investor, signals a lack of confidence or a strategic exit from Larimar Therapeutics. This action typically indicates a negative outlook from a sophisticated investor and could lead to downward pressure on the stock price, suggesting a 'sell' recommendation for current holders or an 'avoid' for potential investors.

Keywords

Larimar Therapeutics, Janus Henderson, Schedule 13G, Institutional Ownership, Common Stock, Investment Divestment, SEC Filing, Biotechnology, Pharmaceuticals